July 6, 2020

CLINICAL UPDATES

ADT-free option shows potential in advanced castration-sensitive prostate cancer

The regimen of apalutamide, abiraterone acetate, and prednisone showed viability in patients with advanced prostate cancer with noncastrate testosterone levels.

Patients undergoing post-URS stent placement more likely to visit ED

Study results show wide variation in stent placement following ureteroscopy.

MORE FROM UROLOGY TIMES

Prostate Ca assay appears similarly predictive of adverse pathology in African American, Caucasian patients

FDA approves avelumab as frontline maintenance in urothelial carcinoma

Twitter

Facebook